Full Press Release Details
Medical Schedules Virtual Meeting to Address Increased Interest Following its Recent Announcement
to be Held on Wednesday August 26th at 11am ET
Mass., August 19, 2020 - Following its participation at the Needham Virtual Med Tech & Diagnostic conference, as
well as the overwhelming interest generated since its recent announcement which included the outcome of a feasibility animal study
with respect to the LIBERTYTM Robotic System, Microbot Medical Inc. (Nasdaq: MBOT) will host a webinar on Wednesday,
August 26, 2020 at 11:00am ET. Harel Gadot, the Company's CEO, President and Chairman, will share the Company's view
on the surgical robotic market, the results of the feasibility animal study, as well as other recent achievements. Additionally,
members of the Company's management team, including Dr. Eyal Morag, Chief Medical Officer, Simon Sharon, Chief Technology
Officer and Eran Cohen, Senior Director of Business Development, will be available for a question and answer session.
participate on the webinar, please register in advance at: https://zoom.us/webinar/register/WN_5JfsfM-aR4WVKdJncgGbvw.
After registering, participants will receive a confirmation email containing information about joining the webinar.
LIBERTYTM Robotic System, which the Company believes to be the first fully disposable surgical robotic system, has
met all of its end points with no intraoperative adverse events. This supports the Company's vision of democratizing endoluminal
procedures while enhancing clinical and economical outcomes. The LIBERTYTM Robotic System has the potential to allow
physicians to conduct catheter-based procedure from outside the catheterization laboratory (cath-lab), avoiding radiation exposure,
physical strain and the risk of cross contamination. The study was performed by two leading physicians in the neuro vascular and
peripheral vascular intervention spaces, and the results demonstrated robust navigation capabilities, intuitive usability and
accurate deployment of embolic agents, most of which was conducted remotely from the cath-lab's control room.
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological
platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes
for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical
is available at http://www.microbotmedical.com.
pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to
future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to
statements that contain words such as "will," "believes," "plans," "anticipates,"
"expects" and "estimates") should also be considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary
closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTYTM,
the outcome of its studies to evaluate the SCS and other existing and future technologies, uncertainty in the results of pre-clinical
and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and
ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot
Medical can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the
Securities and Exchange Commission (SEC) and in the prospectus supplement related to the registered direct offering to be filed
with the SEC, which are or will be available on the SEC's web site at www.sec.gov. Microbot Medical disclaims any intent
or obligation to update these forward-looking statements, except as required by law.